Overview

• Researchers analyzed tumor samples from 87 Western stomach cancer patients, identifying a four-gene mutation signature tied to worse survival outcomes and recurrence rates.
• The study highlights BRCA2, CDH1, RHOA, and TP53 mutations as critical prognostic markers, with BRCA2 showing a broader role beyond breast and ovarian cancers.
• Efforts are underway to develop immunohistochemical assays for routine clinical screening of the identified high-risk genetic profile.
• This research emphasizes the need for personalized treatment strategies, moving away from the traditional one-size-fits-all approach of surgery and chemotherapy.
• Dr. Ulysses Ribeiro will present these findings at Digestive Disease Week on May 3, 2025, with further validation studies and clinical trials anticipated.